



# Creation of a new AS MDT clinic

Dr Francis Kynaston-Pearson, Chloë Kirk, Elizabeth Connor,  
Meg Dubin, Dr Asif Ahmad, Carly Durow

In partnership with:



Sponsored by:



# Disclosures



- Consultancy/speaker fees: *AbbVie, Janssen, Lilly, Uniphar, Mtech access, SERMO surveys*
- Educational grants: *None*
- Research grants: *None*
- Other disclosures: Conference support: *Janssen, AbbVie, Pfizer*
- *Outside employment: Medefer, Private Practice*
- *Share holdings: Diversified index funds*



# Background

## University Hospitals of Derby and Burton NHS Trust


- A large university-affiliated NHS trust, split into two campuses
  - We serve a population of over 1 Million patients
  - Over 12,000 employees
  - Budget of around £1 Billion
- Merger of established Derby and Burton trusts in 2018
  - Integration of services and policies continues – historic inequity between services operated
  - Improvement of care via partnership




# The Derby Team



- Dr Francis Kynaston-Pearson
- Consultant




- Meg Dublin
- Physiotherapist



- Cary Durow
- Nurse



- Chloë Kirk
- Physiotherapist



- Elizabeth Connor
- Nurse



- Dr Asif Ahmad
- Registrar



# Project stages



1

## Concept

- Creating a team
- Service concept & vision
- Shared learning

2

## Pilot planning

- Review of current provision
- Establish key areas for improvement
- Pilot preparation

3

## Pilot delivery

- Clinic booking
- Data capture
- Learning from experience

4

## Evaluation

- Data analysis
- Service revisions
- Financial modelling
- Business case

5

## Service launch

- Commission with ICB
- Promote to primary care and related secondary care specialties
- Ongoing evaluation

# Timeline




# Service Review



- Review of patients on DAWN listed as having Axial Spondyloarthritis/AS and on biologics
- 216 patients identified
- 185 reviewed after removing those with other primary diagnosis or those that had left/died
- From age 25 to 85
- Median 51, Mode 51, Median 49.9
- Longest patient on biologics – 20 years

Gender



■ Male ■ Female

# Treatment choices



## • Biologic choice

Brand	Total
Amgevita	7
Benepali	64
Cimzia	1
Cosentyx	23
Enbrel	10
Erelzi	4
Humira	8
Imraldi	64
Remsima	4

## DMARD Choice

AZA	1
LFL	1
MTX	15
MTX/LFL	1
SZP	6
NA	161

## NSAIDs?

Count of NSAID?		PPI?	
NSAID?	NA	No	Yes
No	120		
Yes		34	31





# Minimum requirements



## Seen and regular BASDAI

Only 135/185 patients were seen in 2022

BASDAI done Total

NA 50

No 51

Yes 84 **(62%)**

Grand Total 185

1 patient moved to Scotland October 2022

1

1 returned Q 11

2 returned Q's 18

2 returned Q's - moved out of area 1

3 returned Q's 42

4 returned Q's 87

5 returned Q's 14


Grand Total 174

**77% returning 3 or more in 12/12**

# Capture of PROMs in clinic letter




## PROMs






# Recorded assessments and interventions

### Assessment/screening



### Advice given



# Other data reviewed




- Presence of Psoriasis
  - +/- capture of PASI scores
- Onward referrals e.g.
  - Physio referrals
  - Specialty nurse referrals





# Project overview

## Driver diagram




# Pilot



- 6 clinics
- 39 patients seen Sept 2023 to March 2024
- Ages from 27 to 79, mean age 55, median and mode both 54.
- New clinic and letter templates created

Pilot demographics




■ Male ■ Female




# Learning through the pilot

## PDSA cycles from each clinic





# Capture of PROMs in pilot vs baseline






# Assessments and interventions

## Pilot vs baseline



### Recorded assessment & interventions in clinic






# Patient satisfaction with pilot


Overall satisfaction – 100% rating “excellent”

Involvement in care



■ Involved (3/3) ■ Could be more involved (2/3)

Quality of information and support



■ Excellent (5/5) ■ Good (4/5)







# Satisfaction

## Patient quotes

- “This is how all the NHS should be run. Couldn't fault, all in one no need to make separate appointments”
- “it was nice to be talked to explaining the test scores. The doctor was helpful explaining things in more detail than previous visits. The new system is a change for the better.”
- “Having attended clinics of such a set up as a child, it was really good to attend one again. I felt that the impact of AS and every aspect of my life was being considered and very helpful suggestions made by all members of the team.”
- “Couldn't wish for better help, injection and xrays - one stop shop”
- “A breath of fresh air, best appointment I've had”



# Conclusions and future plans

- **Successful MDT review clinic pilot**

- ✓ Excellent patient questionnaire feedback
- ✓ Strong team satisfaction with the final clinic model
- ✓ PDSA cycle methodology to support MDT clinic format
- ✓ Template for PROM measurement developed
- ✓ Living well with AS patient handbook in process
- ✓ Future axial spondylarthritis clinic capacity

- **Our future MDT AS clinic**

- ✓ Logistics and approval of business case
- ✓ Move from PROMs on paper to electronic
- ✓ Set up clinic diaries and space to support timings & flow
- ✓ Booking and admin support
- ✓ Set up robust data collection processes/analysis
- ✓ Expand caseload to include AxSpA patients on DMARDs
- ✓ Explore new patient assessment capacity
- ✓ Communications plan to ICB/GP



# References



- Webb D, Zhao S, Whalley S, Hamilton J, Sengupta R & Gaffney K, A Gold Standard Time to Diagnosis in axial Spondyloarthritis: Consultation Document. 2020, NASS
- Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé RBM, Van den Bosch FE, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen FA, Géher P, Gensler L, Hermann J, de Hooge M, Husakova M, Kiltz U, López-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis*. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21. PMID: 36270658.
- Hamilton L, Macgregor A, Toms A, Warmington V, Pinch E, Gaffney K. The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study. *BMC Musculoskelet Disord* [Internet]. 2015;16. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687290/>
- Martindale J, Goodacre L. The Journey to Diagnosis in AS/Axial SpA: The Impact of Delay: The Journey to Diagnosis in AS/Axial SpA. *Musculoskeletal Care*. 2014 Dec;12(4):221–31.